Altos Biologics, a subsidiary of the South Korean biotechnology firm Alteogen Inc., is a company focused on the development and commercialization of biosimilars. One of the company’s flagship products is ALT-L9, a biosimilar to the macular degeneration treatment Eylea® (aflibercept). ALT-L9 has successfully completed a global Phase III clinical trial, which involved over 400 participants across 12 countries. On July 1, 2024, Altos Biologics submitted a Marketing Authorization Application for ALT-L9 to the European Medicines Agency.

At ALTOS Biologics, we're proud to announce the successful launch of our Biomedical Research Initiative, having secured initial investments for our flagship project, SC. This initiative is designed to propel our ongoing efforts in the biomedical field. Our technology has recently achieved a significant milestone through strategic partnerships, supportive policies, and international funding. These accomplishments enable us to advance our research and development efforts, aiming to fulfill global needs. Our objective is to attain a first-mover advantage in the global market by 2025. We are committed to rapidly commercializing our technologies to address market demands, positioning ourselves as a leader in innovation.

Private

Biotech